Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trodelvy vs SOC in Previously Treated ES-SCLC
NCT06801834Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in small cell lung cancer (SCLC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Survival at 4.5 years. Started Apr 2025; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06801834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801834.